Lead Product(s) : Inotersen Sodium
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tegsedi (Inotersen Sodium) is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Amyloid Neuropathies, Familial.
Product Name : Tegsedi
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Inotersen Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
